Tim Brandenburg

Tim Brandenburg

Auto-generated profile, based on publicly available information

Tim Brandenburg

Department of Endocrinology, Diabetes and Metabolism, University Hospital Essen, University of Duisburg-Essen 1

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2023 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
AMAndreas Machens
Andreas Machens
KLKerstin Lorenz
Kerstin Lorenz
TBTim Brandenburg
Tim Brandenburg
DFDagmar Führer-Sakel
Dagmar Führer-Sakel
FWFrank Weber
Frank Weber
HDHenning Dralle
Henning Dralle
Context Early genetic association studies yielded too high risk estimates for multiple endocrine neoplasia (MEN2A), suggesting a need for extended surgery. Objective The objective was to delineate temporal changes in MEN2A presentation by birth cohort analyses. Methods Birth cohort analyses (10-year increments; ≤1950 to 2011–2020) of carriers of rearranged during transfection (RET) mutations who underwent surgery for MEN2A. Results Included in this study were 604 carriers (155 index, 445 nonindex, 4 additional patients), with 237 carriers harboring high risk mutations, 165 carriers moderate–high risk mutations, and 202 carriers low–moderate risk mutations. With increasing recency of birth cohorts, there was a continual decline in index patients from 41–74 to 0% (P<0.001) and medullary thyroid cancer (MTC) from 96–100 to 0–33% (P<0.001). Node metastases diminished from 62–70 to 0% (P≤0.001; high and low–moderate risk mutations), whereas biochemical cure after thyroidectomy surged from 17–33 to 100% (P≤0.019; high and low-moderate mutations). Surgical interventions for MEN2A-related tumors were performed increasingly earlier, causing median carrier age to fall: from 51–63 to 3–5 years at thyroidectomy (P<0.001); from 46–51 to 24–25 years at first adrenalectomy (P≤0.013; high and moderate–high risk mutations); and from 43.5–66 to 16.5–32 years at parathyroidectomy. MTC diameters were more effectively decreased from 14–32 to 1–4 mm (P≤0.002) than pheochromocytoma diameters (nonsignificant). Conclusion These insights into MEN2A presentation, adjusted by birth year, illustrate the shift from reactive to preventative medicine, enabling less extensive risk-reducing surgery.

15 November 2023 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
IVIrfan Vardarli
Irfan Vardarli
STSusanne Tan
Susanne Tan
TBTim Brandenburg
Tim Brandenburg
FWFrank Weidemann
Frank Weidemann
RGRainer Görges
Rainer Görges
DFDagmar Führer
Dagmar Führer
Context: Few meta-analyses on incidence of endocrine immune-related adverse effects (eirAEs) have been published and many trials have been published since. Objective: We performed a comprehensive meta-analysis with updated literature to assess risk and incidence of eirAEs of any grade and grade 3 to 5 by immune checkpoint inhibitor (ICI) monotherapy or combination therapy in solid tumors. Methods: An electronic search using PubMed/Medline, Embase, and the Cochrane Library was performed. Randomized controlled studies (RCTs) assessing eirAEs under ICI monotherapy or ICI combination therapy were selected. Stata software (v17) was used for statistical analyses and risk of bias was evaluated using Review Manager version 5.3. Results: A total of 69 RCTs with 80 independent reports, involving 42 886 patients, were included in the study. Meta-analysis revealed the following pooled estimates for risk ratio and incidence, respectively: for any grade hypothyroidism 7.81 (95% CI, 5.68-10.74, P < .0001) and 7.64% (95% CI, 6.23-9.17, P < .0001); significantly increased also for hyperthyroidism, hypophysitis/hypopituitarism, and adrenal insufficiency; and for insulin-dependent diabetes mellitus 1.52 (95% CI, 1.07-2.18, P = .02), and 0.087% (95% CI, 0.019-0.189, P = .0006), respectively. Meta-regression showed that combination of ICIs (nivolumab plus ipilimumab; durvalumab plus tremelimumab) is an independent risk factor for any grade hypophysitis/hypopituitarism, and that ICI agent is an independent factor of risk for adrenal insufficiency, but that cancer type is not an independent risk factor for eirAEs. Conclusion: We showed that risk, independent from cancer type, and incidence of eirAEs are substantially increased with ICI therapy. Combination of ICIs increases risk for eirAEs, especially for hypophysitis/hypopituitarism.

21 July 2023 in Endocrine
Verified
Journal Article
Closed access
PDF file
AMAndreas Machens
Andreas Machens
KLKerstin Lorenz
Kerstin Lorenz
FWFrank Weber
Frank Weber
TBTim Brandenburg
Tim Brandenburg
DFDagmar Führer-Sakel
Dagmar Führer-Sakel
HDHenning Dralle
Henning Dralle

4 May 2026 in Endocrine
Verified
Journal Article
Open access
SSSusanne Singer
Susanne Singer
KTKatherine Taylor
Katherine Taylor
YMYara Maria Machlah
Yara Maria Machlah
TBTim Brandenburg
Tim Brandenburg
KLKerstin Lorenz
Kerstin Lorenz
FEFriederike Eilsberger
Friederike Eilsberger
Background: Because anaplastic thyroid cancer (ATC) is a rare diagnosis, detailed epidemiological data are difficult to find in publicly accessible platforms. The aim of this study was to report current incidence and survival estimates for ATC in Germany and to analyse their trends over time. Methods: Data from the population-based cancer registries in Germany were pooled. ATC was classified according to the International Classification of Diseases, 10th edition (ICD-10). Age-standardised incidence rates (per 100,000) for the years 2011 to 2022 were calculated. The relative survival was estimated using period analysis. Annual percentage changes (APC) in the incidence and survival trends over time were computed. Findings: The number of new ATC cases diagnosed between 2011 and 2022 was 2127 (924 in men and 1203 in women). The current raw incidence is 0.19 in men and 0.22 in women. The age-standardised incidence in men changed slightly, but not significantly, during this period (APC − 2%, p = 0.126; recent rate 0.11) while it decreased in women (APC − 3%, p < 0.001; recent rate 0.10). The five-year relative survival ranged from 11% (2020–2022) to 15% (2017–2019) and decreased considerably with age. There were no differences in survival between men and women and no evidence for a change in survival over time. Conclusion: About two persons per 1 million inhabitants are currently diagnosed with ATC per year. Over the past 12 years, there was a slight decrease in ATC incidence, especially in women, while survival remained largely unchanged during this period.

26 November 2025 in European Journal of Endocrinology
Verified
Journal Article
Closed access
YMYara Maria Machlah
Yara Maria Machlah
LSLynn Marlene Srasra
Lynn Marlene Srasra
STSarah Theurer
Sarah Theurer
FWFrank Weber
Frank Weber
HLHarald Lahner
Harald Lahner
TBTim Brandenburg
Tim Brandenburg
Objective: Selective RET inhibition with selpercatinib significantly improved outcomes in advanced RET-mutant medullary thyroid cancer (MTC). However, data from endocrine oncology practice are limited, particularly in heterogeneous treatment-naive and pretreated patients. Evaluating real-world effectiveness and safety is essential to reaffirm clinical trial results. Design: Retrospective, single-center study. Methods: We analyzed patients with RET-mutant MTC treated with selpercatinib between March 2021 and May 2025 at the Essen Endocrine Tumor Center. Clinical characteristics, treatment outcomes as well as frequency and longitudinal course of adverse events (AEs) were assessed. Results: Thirty-one patients with advanced RET-mutant MTC (87% with distant metastases; median age 54 years; 84% sporadic) were included. First-line selpercatinib (52%) treatment resulted in significantly longer median progression-free survival (PFS) (not reached vs. 18.3 months) and higher objective response rate (ORR) (81% vs. 33%) compared to later-line use. One-year PFS rate was 100% for first-line and 60% for further-line treatment. ORR was significantly higher in patients without bone metastases (90% vs 43%). Age at treatment initiation, sex, and RET mutation subtype did not impact ORR or PFS. The most common AEs included hypertension (58.6%) and erectile dysfunction (55.6%). Grade ≥3 events occurred in 37.5% of patients, with hypertension most frequent. Treatment interruptions and dose reductions were required in 22.6% of patients, primarily due to QTc prolongation and fatigue. Three patients (9.7%) discontinued treatment permanently due to AEs. Conclusions: In real-word settings, selpercatinib showed high efficacy and tolerability, particularly as first-line treatment. Our findings support its use as the preferred initial targeted treatment for RET-driven MTC beyond clinical trial populations.

23 May 2025 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
YMYara Maria Machlah
Yara Maria Machlah
TBTim Brandenburg
Tim Brandenburg
PMPhilipp Muchalla
Philipp Muchalla
VTVera Tiedje
Vera Tiedje
STSarah Theurer
Sarah Theurer
DFDagmar Führer-Sakel
Dagmar Führer-Sakel
Purpose: Multikinase inhibitors (MKIs) have transformed treatment for advanced radioiodine-refractory differentiated thyroid cancer (RAIR-DTC) and medullary thyroid cancer (MTC). However, limited insight exists into management differences between expert centers and multicenter registries or clinical studies. Moreover, MKI efficacy in poorly differentiated thyroid cancer (PDTC) is underreported. Methods: This retrospective analysis included 154 patients with thyroid cancer (51 PDTC, 49 DTC, 54 MTC) treated with MKIs from 2011 to 2024 at the Essen Endocrine Tumor Center by a consistent specialist team. Clinical characteristics, tumor genetics, time to treatment, and treatment outcomes were assessed. Cox regression analyses identified prognostic survival factors. Results: In (P)DTC, lenvatinib showed higher objective response rate (ORR) (64% vs 18%) and longer median progression-free survival (PFS) (22.4 vs 6.7 months) than sorafenib, especially in PDTC (21.2 vs 3.5 months). Lenvatinib-treated patients without bone metastases had higher ORR (74% vs 53%), while higher age and liver metastases were associated with shorter PFS (HR, 2.12, P = .039; HR, 2.34, P = .031). In MTC, vandetanib demonstrated higher ORR (60% vs 18%) and longer PFS (26.1 vs 10.0 months) than cabozantinib. Vandetanib as first-line showed higher ORR (67% vs 25%) and RET mutations correlated with longer PFS (HR, 0.14, P = .045). Conclusion: Lenvatinib outperformed sorafenib, particularly in PDTC, suggesting the need for alternative treatments. In MTC, vandetanib was more effective than cabozantinib, supporting its use as first-line therapy. However, the choice of MKI was determined by the treating physician. Our data highlight MKI effectiveness under expert-center management compared to prior trials and real-world data.